Leerink Partnrs Has Pessimistic View of Oculis Q2 Earnings

Oculis Holding AG (NASDAQ:OCS) – Equities research analysts at Leerink Partnrs lowered their Q2 2025 earnings per share estimates for Oculis in a research note issued to investors on Wednesday, June 4th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of ($0.50) per share for the quarter, down from their previous estimate of ($0.48). The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. Leerink Partnrs also issued estimates for Oculis’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.51) EPS, FY2026 earnings at ($2.26) EPS, FY2027 earnings at ($3.49) EPS, FY2028 earnings at ($2.20) EPS and FY2029 earnings at $0.43 EPS.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. The company had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $0.22 million.

Other equities research analysts have also issued reports about the company. HC Wainwright lifted their price target on Oculis from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, April 17th. Chardan Capital lifted their price target on shares of Oculis from $28.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, May 9th. Finally, Robert W. Baird boosted their price objective on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th.

Oculis Trading Down 0.7%

Shares of OCS opened at $19.79 on Monday. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. Oculis has a 1-year low of $10.79 and a 1-year high of $23.08. The firm’s 50-day moving average price is $17.99 and its 200-day moving average price is $18.80. The firm has a market capitalization of $864.07 million, a price-to-earnings ratio of -10.25 and a beta of 0.35.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in OCS. Pivotal bioVenture Partners Investment Advisor LLC lifted its stake in shares of Oculis by 32.4% in the first quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock worth $43,784,000 after buying an additional 563,078 shares in the last quarter. SR One Capital Management LP bought a new position in shares of Oculis in the first quarter worth approximately $6,137,000. Aberdeen Group plc lifted its position in Oculis by 24.1% during the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock valued at $23,847,000 after purchasing an additional 243,695 shares during the period. Alyeska Investment Group L.P. bought a new position in Oculis during the first quarter valued at approximately $2,499,000. Finally, Citadel Advisors LLC bought a new position in Oculis during the fourth quarter valued at approximately $389,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.